Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,121 to 1,140 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers. | Front Immunol | 2022 | 35844493 | PubTator, text mining | PubMed |
| Emerging strategies to overcome resistance to third-generation EGFR inhibitors. | J Hematol Oncol | 2022 | 35840984 | PubTator, text mining | PubMed |
| A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. | Pathol Oncol Res | 2022 | 35832114 | PubTator, text mining | PubMed |
| [Development of novel cereblon modulators and their target molecules]. | Rinsho Ketsueki | 2022 | 35831190 | PubTator, text mining | PubMed |
| Development of Rapid and Facile Solid-Phase Synthesis of PROTACs via a Variety of Binding Styles. | ChemistryOpen | 2022 | 35822913 | PubTator, text mining | PubMed |
| Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One. | J Med Chem | 2022 | 35816671 | PubTator, text mining | PubMed |
| Major Advances in Emerging Degrader Technologies. | Front Cell Dev Biol | 2022 | 35813205 | PubTator, text mining | PubMed |
| Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives. | Int J Mol Sci | 2022 | 35806308 | PubTator, text mining | PubMed |
| Protein-Protein Interaction Prediction for Targeted Protein Degradation. | Int J Mol Sci | 2022 | 35806036 | PubTator, text mining | PubMed |
| Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma. | Cancers (Basel) | 2022 | 35804999 | PubTator, text mining | PubMed |
| Liquid-liquid phase separation in tumor biology. | Signal Transduct Target Ther | 2022 | 35803926 | PubTator, text mining | PubMed |
| Immunotherapy for KSHV-associated diseases. | Curr Opin Virol | 2022 | 35803203 | PubTator, text mining | PubMed |
| E3 ubiquitin ligase RBX1 drives the metastasis of triple negative breast cancer through a FBXO45-TWIST1-dependent degradation mechanism. | Aging (Albany NY) | 2022 | 35802537 | PubTator, text mining | PubMed |
| Cancer drug resistance in multiple myeloma. | Cancer Drug Resist | 2022 | 35800374 | PubTator, text mining | PubMed |
| Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. | Chem Soc Rev | 2022 | 35796627 | PubTator, text mining | PubMed |
| Cell Morphological Profiling Enables High-Throughput Screening for PROteolysis TArgeting Chimera (PROTAC) Phenotypic Signature. | ACS Chem Biol | 2022 | 35793809 | PubTator, text mining | PubMed |
| The Casein kinase 1α agonist pyrvinium attenuates Wnt-mediated CK1α degradation via interaction with the E3 ubiquitin ligase component Cereblon. | J Biol Chem | 2022 | 35780831 | PubTator, text mining | PubMed |
| What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. | Target Oncol | 2022 | 35771402 | PubTator, text mining | PubMed |
| Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population. | Technol Cancer Res Treat | 2022 | 35770320 | PubTator, text mining | PubMed |
| The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. | Nat Commun | 2022 | 35768438 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=57